MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity

Abstract Background This study explored the role of Mannose-Binding Lectin-Associated Serine Protease 1 (MASP1) in the diagnosis, prognosis, and immune landscape of stomach adenocarcinoma (STAD), with the aim of providing a molecular foundation for developing early, non-invasive diagnostic tools and...

Full description

Saved in:
Bibliographic Details
Main Authors: Chuyu Xiao, Fuyang Hong, Guanzi Chen, Wenli Xu, Yusheng Jie
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-02900-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849764648676491264
author Chuyu Xiao
Fuyang Hong
Guanzi Chen
Wenli Xu
Yusheng Jie
author_facet Chuyu Xiao
Fuyang Hong
Guanzi Chen
Wenli Xu
Yusheng Jie
author_sort Chuyu Xiao
collection DOAJ
description Abstract Background This study explored the role of Mannose-Binding Lectin-Associated Serine Protease 1 (MASP1) in the diagnosis, prognosis, and immune landscape of stomach adenocarcinoma (STAD), with the aim of providing a molecular foundation for developing early, non-invasive diagnostic tools and advancing immunotherapeutic strategies. Methods We analyzed STAD messenger RNA (mRNA) data from The Cancer Genome Atlas (TCGA), immune-related gene data from the ImmPort database, and complement system-related genes from previous studies. Differentially expressed mRNAs (DEmRNAs) relevant to prognosis, immunity, and the complement system were identified using the “limma” and “survival” packages, alongside a Venn diagram. We confirmed MASP1 expression through analysis of external databases, as well as performing quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting (WB) on the normal gastric cell line and various gastric cancer cell lines. The diagnostic performance of MASP1 was evaluated through Receiver Operating Characteristic (ROC) curve analysis using the “pROC” package. Chi-square tests were conducted to examine the association between MASP1 expression and clinicopathological factors. Univariate and multivariate Cox regression analyses were performed to quantify the survival impact of MASP1 expression. Enrichment analyses were conducted to elucidate the functions and pathways associated with MASP1. The relationship between MASP1 expression and tumor immune infiltration was analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA), Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT), Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE), and Spearman correlation methods. Result Our findings demonstrated that MASP1 is a significant biomarker associated with immune response and prognosis in STAD patients. Elevated MASP1 expression was correlated with poorer clinical outcomes, with ROC curve analysis revealing an Area Under the Curve (AUC) of 0.725 for MASP1. Additionally, MASP1 was identified as an independent prognostic marker for overall survival (OS) in STAD patients. The expression of MASP1 in STAD was predominantly linked to DNA damage repair and cell cycle regulation mechanisms. Furthermore, MASP1 expression showed a significant association with tumor-infiltrating immune cells and immune-related molecules. Conclusion This study highlights the significant correlation between MASP1 and the immunological landscape of STAD. MASP1 has the potential to serve as a diagnostic and prognostic marker and could be a promising therapeutic target for immunotherapy in STAD.
format Article
id doaj-art-4c37c1ca99ac4373a32e4d75c5a45dee
institution DOAJ
issn 2730-6011
language English
publishDate 2025-06-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-4c37c1ca99ac4373a32e4d75c5a45dee2025-08-20T03:05:05ZengSpringerDiscover Oncology2730-60112025-06-0116112410.1007/s12672-025-02900-wMASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunityChuyu Xiao0Fuyang Hong1Guanzi Chen2Wenli Xu3Yusheng Jie4The Third Affiliated Hospital of Sun Yat-sen UniversityThe Third Affiliated Hospital of Sun Yat-sen UniversityThe Third Affiliated Hospital of Sun Yat-sen UniversityDivision of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical UniversityThe Third Affiliated Hospital of Sun Yat-sen UniversityAbstract Background This study explored the role of Mannose-Binding Lectin-Associated Serine Protease 1 (MASP1) in the diagnosis, prognosis, and immune landscape of stomach adenocarcinoma (STAD), with the aim of providing a molecular foundation for developing early, non-invasive diagnostic tools and advancing immunotherapeutic strategies. Methods We analyzed STAD messenger RNA (mRNA) data from The Cancer Genome Atlas (TCGA), immune-related gene data from the ImmPort database, and complement system-related genes from previous studies. Differentially expressed mRNAs (DEmRNAs) relevant to prognosis, immunity, and the complement system were identified using the “limma” and “survival” packages, alongside a Venn diagram. We confirmed MASP1 expression through analysis of external databases, as well as performing quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting (WB) on the normal gastric cell line and various gastric cancer cell lines. The diagnostic performance of MASP1 was evaluated through Receiver Operating Characteristic (ROC) curve analysis using the “pROC” package. Chi-square tests were conducted to examine the association between MASP1 expression and clinicopathological factors. Univariate and multivariate Cox regression analyses were performed to quantify the survival impact of MASP1 expression. Enrichment analyses were conducted to elucidate the functions and pathways associated with MASP1. The relationship between MASP1 expression and tumor immune infiltration was analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA), Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT), Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE), and Spearman correlation methods. Result Our findings demonstrated that MASP1 is a significant biomarker associated with immune response and prognosis in STAD patients. Elevated MASP1 expression was correlated with poorer clinical outcomes, with ROC curve analysis revealing an Area Under the Curve (AUC) of 0.725 for MASP1. Additionally, MASP1 was identified as an independent prognostic marker for overall survival (OS) in STAD patients. The expression of MASP1 in STAD was predominantly linked to DNA damage repair and cell cycle regulation mechanisms. Furthermore, MASP1 expression showed a significant association with tumor-infiltrating immune cells and immune-related molecules. Conclusion This study highlights the significant correlation between MASP1 and the immunological landscape of STAD. MASP1 has the potential to serve as a diagnostic and prognostic marker and could be a promising therapeutic target for immunotherapy in STAD.https://doi.org/10.1007/s12672-025-02900-wMASP1Stomach adenocarcinomaImmune infiltrationImmune checkpoint
spellingShingle Chuyu Xiao
Fuyang Hong
Guanzi Chen
Wenli Xu
Yusheng Jie
MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
Discover Oncology
MASP1
Stomach adenocarcinoma
Immune infiltration
Immune checkpoint
title MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
title_full MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
title_fullStr MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
title_full_unstemmed MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
title_short MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity
title_sort masp1 in stomach adenocarcinoma linking diagnosis prognosis and tumor immunity
topic MASP1
Stomach adenocarcinoma
Immune infiltration
Immune checkpoint
url https://doi.org/10.1007/s12672-025-02900-w
work_keys_str_mv AT chuyuxiao masp1instomachadenocarcinomalinkingdiagnosisprognosisandtumorimmunity
AT fuyanghong masp1instomachadenocarcinomalinkingdiagnosisprognosisandtumorimmunity
AT guanzichen masp1instomachadenocarcinomalinkingdiagnosisprognosisandtumorimmunity
AT wenlixu masp1instomachadenocarcinomalinkingdiagnosisprognosisandtumorimmunity
AT yushengjie masp1instomachadenocarcinomalinkingdiagnosisprognosisandtumorimmunity